Name
As of 03/26/2024Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
Vitals
YTD Return
7.8%
1 yr return
10.5%
3 Yr Avg Return
-3.1%
5 Yr Avg Return
3.9%
Net Assets
$125 M
Holdings in Top 10
53.3%
52 WEEK LOW AND HIGH
Expenses
OPERATING FEES
Expense Ratio 1.95%
SALES FEES
Front Load N/A
Deferred Load 1.00%
TRADING FEES
Turnover 152.78%
Redemption Fee N/A
Min Investment
Standard (Taxable)
$1,000
IRA
$500
Fund Classification
Fund Type
Open End Mutual Fund
Name
As of 03/26/2024Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
AHSCX - Profile
Distributions
- YTD Total Return 7.8%
- 3 Yr Annualized Total Return -3.1%
- 5 Yr Annualized Total Return 3.9%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -1.39%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annual
Fund Details
-
Legal NameAlger Health Sciences Fund
-
Fund Family NameAlger Family of Funds
-
Inception DateMay 01, 2002
-
Shares OutstandingN/A
-
Share ClassC
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerDaniel Chung
Fund Description
AHSCX - Performance
Return Ranking - Trailing
Period | AHSCX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | 7.8% | -15.0% | 17.3% | 46.01% |
1 Yr | 10.5% | -20.2% | 35.0% | 74.85% |
3 Yr | -3.1%* | -30.8% | 14.0% | 82.69% |
5 Yr | 3.9%* | -3.5% | 14.3% | 87.50% |
10 Yr | 3.1%* | 0.2% | 14.1% | 97.20% |
* Annualized
Return Ranking - Calendar
Period | AHSCX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | -5.1% | -12.6% | 19.0% | 93.25% |
2022 | -17.7% | -53.9% | 3.2% | 79.49% |
2021 | -29.4% | -39.6% | 24.2% | 98.72% |
2020 | 11.5% | -13.6% | 178.2% | 58.94% |
2019 | 10.7% | 3.8% | 63.8% | 95.56% |
Total Return Ranking - Trailing
Period | AHSCX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | 7.8% | -15.0% | 17.3% | 46.01% |
1 Yr | 10.5% | -20.2% | 35.0% | 74.85% |
3 Yr | -3.1%* | -30.8% | 14.0% | 82.69% |
5 Yr | 3.9%* | -3.5% | 14.3% | 87.50% |
10 Yr | 3.1%* | 0.2% | 14.1% | 97.20% |
* Annualized
Total Return Ranking - Calendar
Period | AHSCX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | -5.1% | -12.6% | 19.0% | 95.09% |
2022 | -17.7% | -53.9% | 3.7% | 84.62% |
2021 | 1.7% | -33.9% | 26.0% | 75.64% |
2020 | 30.0% | -0.7% | 180.6% | 33.77% |
2019 | 21.1% | 4.6% | 63.8% | 82.22% |
NAV & Total Return History
AHSCX - Holdings
Concentration Analysis
AHSCX | Category Low | Category High | AHSCX % Rank | |
---|---|---|---|---|
Net Assets | 125 M | 6.16 M | 45 B | 72.39% |
Number of Holdings | 50 | 23 | 413 | 77.30% |
Net Assets in Top 10 | 62.8 M | 2.07 M | 20.4 B | 71.17% |
Weighting of Top 10 | 53.29% | 18.1% | 77.0% | 26.99% |
Top 10 Holdings
- UNITEDHEALTH GROUP INC 0.00000000 9.28%
- HUMANA INC 0.00000000 8.28%
- IMPULSE DYNAMICS IRELAND 0.00000000 5.23%
- AMGEN INC 0.00000000 4.96%
- MCKESSON CORP 0.00000000 4.81%
- REGENERON PHARMACEUTICALS 0.00000000 4.59%
- ELI LILLY CO 0.00000000 4.30%
- VERTEX PHARMACEUTICALS INC 0.00000000 4.23%
- CIGNA CORP 0.00000000 4.07%
- ABBVIE INC 0.00000000 3.53%
Asset Allocation
Weighting | Return Low | Return High | AHSCX % Rank | |
---|---|---|---|---|
Stocks | 95.18% | 87.17% | 106.13% | 68.10% |
Cash | 4.82% | 0.00% | 32.99% | 26.99% |
Preferred Stocks | 0.00% | 0.00% | 7.86% | 50.92% |
Other | 0.00% | -22.99% | 17.73% | 52.15% |
Convertible Bonds | 0.00% | 0.00% | 0.37% | 34.81% |
Bonds | 0.00% | 0.00% | 12.39% | 37.42% |
Stock Sector Breakdown
Weighting | Return Low | Return High | AHSCX % Rank | |
---|---|---|---|---|
Healthcare | 100.00% | 59.26% | 100.00% | 17.72% |
Utilities | 0.00% | 0.00% | 0.00% | 30.38% |
Technology | 0.00% | 0.00% | 22.69% | 36.71% |
Real Estate | 0.00% | 0.00% | 5.89% | 34.18% |
Industrials | 0.00% | 0.00% | 7.02% | 36.08% |
Financial Services | 0.00% | 0.00% | 1.60% | 48.73% |
Energy | 0.00% | 0.00% | 0.00% | 30.38% |
Communication Services | 0.00% | 0.00% | 9.11% | 33.54% |
Consumer Defense | 0.00% | 0.00% | 25.73% | 39.87% |
Consumer Cyclical | 0.00% | 0.00% | 1.92% | 36.08% |
Basic Materials | 0.00% | 0.00% | 7.16% | 55.06% |
Stock Geographic Breakdown
Weighting | Return Low | Return High | AHSCX % Rank | |
---|---|---|---|---|
US | 90.79% | 66.21% | 104.41% | 58.28% |
Non US | 4.39% | 0.00% | 29.78% | 41.10% |
AHSCX - Expenses
Operational Fees
AHSCX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Expense Ratio | 1.95% | 0.08% | 4.28% | 19.63% |
Management Fee | 0.55% | 0.03% | 1.25% | 20.86% |
12b-1 Fee | 1.00% | 0.00% | 1.00% | 83.33% |
Administrative Fee | 0.03% | 0.03% | 0.25% | 5.26% |
Sales Fees
AHSCX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Front Load | N/A | 3.50% | 5.75% | N/A |
Deferred Load | 1.00% | 1.00% | 5.00% | 38.10% |
Trading Fees
AHSCX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Max Redemption Fee | N/A | 1.00% | 1.00% | 21.95% |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
AHSCX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Turnover | 152.78% | 0.00% | 238.00% | 96.38% |
AHSCX - Distributions
Dividend Yield Analysis
AHSCX | Category Low | Category High | AHSCX % Rank | |
---|---|---|---|---|
Dividend Yield | 0.00% | 0.00% | 6.95% | 57.67% |
Dividend Distribution Analysis
AHSCX | Category Low | Category High | Category Mod | |
---|---|---|---|---|
Dividend Distribution Frequency | Annual | Annual | Monthly | Annual |
Net Income Ratio Analysis
AHSCX | Category Low | Category High | AHSCX % Rank | |
---|---|---|---|---|
Net Income Ratio | -1.39% | -2.54% | 1.85% | 94.23% |
Capital Gain Distribution Analysis
AHSCX | Category Low | Category High | Capital Mode | |
---|---|---|---|---|
Capital Gain Distribution Frequency | Annually | Annually | Annually | Annually |
AHSCX - Fund Manager Analysis
Managers
Daniel Chung
Start Date
Tenure
Tenure Rank
Oct 01, 2005
16.67
16.7%
Dan Chung, CFA is Chief Executive Officer, Chief Investment Officer and Portfolio Manager of several Alger strategies. Dan joined Alger in 1994 and has 27 years of investment experience. He was named Chief Investment Officer in September 2001, President in 2003, and CEO in 2006. Dan is also a member of The Alger Partners Plan. Throughout his tenure at Alger, he has made numerous TV appearances on Bloomberg, CNBC, and Fox Business. Dan has also been featured and quoted frequently in Barron’s, Citywire, Forbes, Investment News, Pensions & Investments, and USA Today. Prior to joining Alger, Dan was an associate at Simpson Thacher & Bartlett LLP in New York City in 1989 while he earned an LL.M. from New York University. He earned his J.D. magna cum laude from Harvard Law School in 1987, where he was an editor of the Harvard Law Review. After graduating, he served as law clerk for the Honorable Justice Anthony M. Kennedy, United States Supreme Court. Dan graduated from Stanford University with B.A. and B.S. degrees, with Distinction and Phi Beta Kappa, in 1984. Dan is also a CFA charterholder and a member of the CFA Institute. Dan currently serves as a board trustee and former chairman of The Nature Conservancy in the State of New York and is a Global Campaign Committee Member of The Nature Conservancy. He is also actively involved with the Stanford in New York Internship Program, and frequently contributes to and supports various charitable organizations including the Harlem Education Activities Fund (HEAF) and Target Margin Theater.
Sanjiv Talwar
Start Date
Tenure
Tenure Rank
Jul 01, 2021
0.92
0.9%
Dr. Sanjiv Talwar is Senior Vice President, Senior Analyst, Portfolio Manager of the Alger Health Sciences and Large Cap Growth strategies and the Head of Healthcare. He joined Alger in 2021 with 15 years of investment experience and more than 12 years of experience in scientific and medical research. Before joining Alger, Sanjiv was a Portfolio Manager, Senior Analyst and Director of Equity Research for Oppenheimer Funds, a life sciences fund from 2012 to 2021 at Invesco, where he also served as a Senior Healthcare Analyst on a global fund. Prior to that, Sanjiv was an Associate Principal at McKinsey & Company from 2006 to 2012, where he led consulting teams focused on healthcare, serving industry and private equity globally.
Tenure Analysis
Category Low | Category High | Category Average | Category Mode |
---|---|---|---|
0.02 | 24.72 | 7.84 | 0.25 |